NCT00266279View on ClinicalTrials.gov

Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Head or Neck Cancer
Interventions
DRUG

Oxaliplatin, Capecitabine

"Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21"

Trial Locations (1)

40202

University of Louisville, James Graham Brown Cancer Center, Louisville

All Listed Sponsors
collaborator

James Graham Brown Cancer Center

OTHER

lead

University of Louisville

OTHER

NCT00266279 - Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies | Biotech Hunter | Biotech Hunter